LED Medical Diagnostics Inc.
TSX VENTURE : LMD
OTCQX : LEDIF
FRANKFURT : LME

LED Medical Diagnostics Inc.

January 21, 2014 08:00 ET

LED Medical Inc. Announces Distribution Agreement with Patterson Dental

BURNABY, BRITISH COLUMBIA--(Marketwired - Jan. 21, 2014) - LED Medical Diagnostics Inc. ("LED Medical" or the "Company") (TSX VENTURE:LMD) (OTCQX:LEDIF) (FRANKFURT:LME) is pleased to announce that its wholly-owned U.S. subsidiary, LED Dental Inc. ("LED Dental"), has entered into a non-exclusive partnership with Patterson Dental for the distribution of the company's VELscope® Vx Enhanced Oral Assessment System and product line within the US and Canadian markets.

"We are pleased to welcome Patterson Dental as our newest U.S. distribution partner for the VELscope® Vx family of products," stated Dr. David Gane, CEO of LED Medical. "Patterson Dental is one of the most respected names in North America, with an exemplary reputation for providing innovative products and focusing on the success of its customers," added Dr. Gane. "With more than 85 branch offices nationwide and over 1,500 sales representatives and equipment specialists, Patterson Dental is a valued distribution partner for LED Dental."

"The VELscope® Vx product line is an important addition to the wide range of products we provide to our customers," states Paul Guggenheim, president of Patterson Dental. "With its powerful and proven tissue fluorescence technology, the VELscope® Vx device provides important visual information that can help dentists detect oral abnormalities sooner than with the naked eye. We are excited to bring this product to our customers to supplement the high level of oral care they already provide."

About the VELscope® Vx Enhanced Oral Assessment System

The distinctive blue-spectrum light of the VELscope® Vx hand-held device causes the soft tissues of the mouth to naturally fluoresce. Healthy tissues fluoresce in distinct patterns that are visibly disrupted by trauma or disease, such as neoplastic lesions, chemical irritation, side-effects from medication, thermal damage, fungal, viral or bacterial infections. Use of the VELscope® Vx allows a wide variety of oral abnormalities to be discovered, often before they're visible to the unassisted eye. It is also the only tissue fluorescence device with photo/video documentation capabilities through the viewing mechanism, a key function for referrals and patient records.

About Patterson Dental

Patterson Dental, a leading distributor of dental products, equipment and technology in the U.S. and Canada, serves as the largest business in the progressive, global Patterson Companies (Nasdaq: PDCO) family of businesses. Patterson is committed to creating value for customers through products, services and lasting relationships. Dental professionals who partner with Patterson enjoy the convenience and peace of mind that come with relying on one trusted source for everything they need. For more details, visit www.pattersondental.com.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED‐based visualization technologies for the medical industries. The Company is currently listed on the TSX Venture Exchange (TSX.V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.

Through its wholly‐owned subsidiaries, LED Dental Inc. (Canada) and LED Dental Ltd. (USA), the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope® Vx systems sold globally and they have been used to perform more than 25 million exams. For more information, call 604.434.4614 or visit www.leddental.com.

Forward-Looking Statements

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding its future distribution strategy. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2012. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • LED Medical Diagnostics Inc.
    Mark Komonoski, Investor Relations
    (403) 255.8483 or Toll-Free: 877.255.8483
    Cell: (403) 470.8384
    mark.komonoski@ledmd.com
    Skype: mkomonoski